Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166620517> ?p ?o ?g. }
- W2166620517 endingPage "e75088" @default.
- W2166620517 startingPage "e75088" @default.
- W2166620517 abstract "Lipid-lowering drugs are used for the prevention of cardiovascular diseases. Statins are the most commonly used lipid-lowering drugs. Evidence from preclinical and observational studies suggests that statins might improve the prognosis of breast cancer patients. We analyzed data from the German MARIEplus study, a large prospective population-based cohort of patients aged 50 and older, who were diagnosed with breast cancer between 2001 and 2005. For overall mortality, breast-cancer specific mortality, and non-breast-cancer mortality, we included 3189 patients with invasive breast cancer stage I-IV, and for recurrence risk 3024 patients with breast cancer stage I-III. We used Cox proportional hazards models to assess the association with self-reported lipid-lowering drug use at recruitment. We stratified by study region, tumor grade, and estrogen/progesterone receptor status, and adjusted for age, tumor size, nodal status, metastases (stage I-IV only), menopausal hormone treatment, mode of detection, radiotherapy, and smoking. Mortality analyses were additionally adjusted for cardiovascular disease, diabetes mellitus and body-mass index. During a median follow-up of 5.3 years, 404 of 3189 stage I-IV patients died, and 286 deaths were attributed to breast cancer. Self-reported use of lipid-lowering drugs was non-significantly associated with increased non-breast cancer mortality (Hazard ratio (HR) 1.49, 95% confidence interval (CI) 0.88-2.52) and increased overall mortality (HR 1.21, 95% CI 0.87-1.69) whereas no association with breast cancer-specific mortality was found (HR 1.04, 0.67-1.60). Restricted to stage I-III breast cancer patients, 387 recurrences occurred during a median follow-up of 5.4 years. We found lipid-lowering drug use to be non-significantly associated with a reduced risk of recurrence (HR 0.83, 95% CI 0.54-1.24) and of breast cancer-specific mortality (HR 0.89, 95% CI 0.52-1.49). Although compatible with previous findings of an improved prognosis associated with statin use, our results do not provide clear supportive evidence for an association with lipid-lowering drug use due to imprecise estimates." @default.
- W2166620517 created "2016-06-24" @default.
- W2166620517 creator A5020564648 @default.
- W2166620517 creator A5054487026 @default.
- W2166620517 creator A5058271369 @default.
- W2166620517 creator A5066620339 @default.
- W2166620517 creator A5067877971 @default.
- W2166620517 creator A5072504667 @default.
- W2166620517 creator A5073405532 @default.
- W2166620517 date "2013-09-25" @default.
- W2166620517 modified "2023-10-16" @default.
- W2166620517 title "Mortality and Recurrence Risk in Relation to the Use of Lipid-Lowering Drugs in a Prospective Breast Cancer Patient Cohort" @default.
- W2166620517 cites W1535819521 @default.
- W2166620517 cites W1570622790 @default.
- W2166620517 cites W1974196451 @default.
- W2166620517 cites W1981643311 @default.
- W2166620517 cites W1984262040 @default.
- W2166620517 cites W1993151230 @default.
- W2166620517 cites W2023622283 @default.
- W2166620517 cites W2034948055 @default.
- W2166620517 cites W2037565051 @default.
- W2166620517 cites W2037877663 @default.
- W2166620517 cites W2058647728 @default.
- W2166620517 cites W2076405790 @default.
- W2166620517 cites W2077509211 @default.
- W2166620517 cites W2103213014 @default.
- W2166620517 cites W2114927900 @default.
- W2166620517 cites W2133101207 @default.
- W2166620517 cites W2153181024 @default.
- W2166620517 cites W2153810797 @default.
- W2166620517 cites W2477541748 @default.
- W2166620517 cites W3140388327 @default.
- W2166620517 cites W4362223089 @default.
- W2166620517 doi "https://doi.org/10.1371/journal.pone.0075088" @default.
- W2166620517 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3783471" @default.
- W2166620517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24086446" @default.
- W2166620517 hasPublicationYear "2013" @default.
- W2166620517 type Work @default.
- W2166620517 sameAs 2166620517 @default.
- W2166620517 citedByCount "47" @default.
- W2166620517 countsByYear W21666205172014 @default.
- W2166620517 countsByYear W21666205172015 @default.
- W2166620517 countsByYear W21666205172016 @default.
- W2166620517 countsByYear W21666205172017 @default.
- W2166620517 countsByYear W21666205172018 @default.
- W2166620517 countsByYear W21666205172019 @default.
- W2166620517 countsByYear W21666205172020 @default.
- W2166620517 countsByYear W21666205172021 @default.
- W2166620517 countsByYear W21666205172022 @default.
- W2166620517 countsByYear W21666205172023 @default.
- W2166620517 crossrefType "journal-article" @default.
- W2166620517 hasAuthorship W2166620517A5020564648 @default.
- W2166620517 hasAuthorship W2166620517A5054487026 @default.
- W2166620517 hasAuthorship W2166620517A5058271369 @default.
- W2166620517 hasAuthorship W2166620517A5066620339 @default.
- W2166620517 hasAuthorship W2166620517A5067877971 @default.
- W2166620517 hasAuthorship W2166620517A5072504667 @default.
- W2166620517 hasAuthorship W2166620517A5073405532 @default.
- W2166620517 hasBestOaLocation W21666205171 @default.
- W2166620517 hasConcept C121608353 @default.
- W2166620517 hasConcept C126322002 @default.
- W2166620517 hasConcept C143998085 @default.
- W2166620517 hasConcept C188816634 @default.
- W2166620517 hasConcept C207103383 @default.
- W2166620517 hasConcept C2780221984 @default.
- W2166620517 hasConcept C2908647359 @default.
- W2166620517 hasConcept C44249647 @default.
- W2166620517 hasConcept C50382708 @default.
- W2166620517 hasConcept C530470458 @default.
- W2166620517 hasConcept C71924100 @default.
- W2166620517 hasConcept C99454951 @default.
- W2166620517 hasConceptScore W2166620517C121608353 @default.
- W2166620517 hasConceptScore W2166620517C126322002 @default.
- W2166620517 hasConceptScore W2166620517C143998085 @default.
- W2166620517 hasConceptScore W2166620517C188816634 @default.
- W2166620517 hasConceptScore W2166620517C207103383 @default.
- W2166620517 hasConceptScore W2166620517C2780221984 @default.
- W2166620517 hasConceptScore W2166620517C2908647359 @default.
- W2166620517 hasConceptScore W2166620517C44249647 @default.
- W2166620517 hasConceptScore W2166620517C50382708 @default.
- W2166620517 hasConceptScore W2166620517C530470458 @default.
- W2166620517 hasConceptScore W2166620517C71924100 @default.
- W2166620517 hasConceptScore W2166620517C99454951 @default.
- W2166620517 hasIssue "9" @default.
- W2166620517 hasLocation W21666205171 @default.
- W2166620517 hasLocation W21666205172 @default.
- W2166620517 hasLocation W21666205173 @default.
- W2166620517 hasLocation W21666205174 @default.
- W2166620517 hasLocation W21666205175 @default.
- W2166620517 hasLocation W21666205176 @default.
- W2166620517 hasOpenAccess W2166620517 @default.
- W2166620517 hasPrimaryLocation W21666205171 @default.
- W2166620517 hasRelatedWork W1727188710 @default.
- W2166620517 hasRelatedWork W2074568790 @default.
- W2166620517 hasRelatedWork W2119154902 @default.
- W2166620517 hasRelatedWork W2133235702 @default.
- W2166620517 hasRelatedWork W2154462701 @default.
- W2166620517 hasRelatedWork W2203903734 @default.